Lonnel Coats, Lexicon Pharmaceuticals CEO
FDA again spells out safety concerns with oral type 1 diabetes drug while denying Lexicon's attempt to overturn a CRL
Back in March 2019, the FDA made clear to Sanofi and its partner Lexicon Pharmaceuticals — Sanofi has since left the picture — that it couldn …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
